Haemonetics Corporation HAE
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About HAE
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Haemonetics Corporation is a U.S.-based medical technology company focused on blood and plasma collection, hospital transfusion management, and hemostasis management solutions. The company operates within the broader healthcare equipment and medical devices industry, serving blood centers, plasma collection operators, hospitals, surgical centers, and healthcare providers. Its core revenue drivers include plasma collection systems, blood management technologies, disposables used in recurring clinical procedures, and software platforms supporting transfusion and patient blood management workflows.
The company’s primary business segments include Plasma, Blood Center, and Hospital operations. Haemonetics has developed a strong competitive position through its installed base of automated collection devices, recurring consumables revenue model, and long-standing relationships with plasma collection companies and healthcare institutions. Founded in 1971 and headquartered in Boston, Massachusetts, the company initially focused on automated blood collection technologies and later expanded through acquisitions and product development into hospital blood management, surgical technologies, and digital clinical software platforms.
Business Operations
Haemonetics generates revenue through sales of medical devices, software systems, and high-margin disposable products used in blood and plasma collection procedures. Its Plasma business supplies automated plasma collection systems and related consumables to commercial plasma collectors, while the Blood Center segment supports blood collection agencies with apheresis and whole blood technologies. The Hospital segment includes cell salvage systems, transfusion management software, hemostasis diagnostics, and interventional technologies used in cardiovascular and surgical settings.
The company operates across both domestic and international markets, with meaningful operations in North America, Europe, Asia-Pacific, and parts of Latin America. Haemonetics controls a portfolio of proprietary technologies related to blood component separation, donor management, and hemostatic monitoring. Major acquisitions have included Pall Corporation’s blood management assets, Cardiva Medical, and OpSens Inc., which expanded the company’s cardiovascular and vascular closure capabilities. The company also maintains strategic customer relationships with leading plasma collection organizations and healthcare systems globally.
Strategic Position & Investments
Haemonetics has increasingly focused its strategy on higher-growth and higher-margin plasma and hospital technologies while streamlining lower-growth legacy operations. A major strategic initiative has been expansion within the plasma collection market, where increasing global demand for plasma-derived therapies has supported investment in collection efficiency technologies and donor throughput optimization. The company has also emphasized software-enabled hospital solutions, procedural technologies, and cardiovascular intervention products.
Recent acquisitions and investments have strengthened Haemonetics’ position in interventional cardiology and vascular access. The acquisition of Cardiva Medical added vascular closure technologies, while the acquisition of OpSens Inc. expanded the company’s portfolio into fractional flow reserve and optical diagnostic technologies used in cardiovascular procedures. Haemonetics has also invested in digital and data-driven clinical platforms designed to improve procedural outcomes, blood utilization efficiency, and operational management for healthcare providers.
Geographic Footprint
Haemonetics is headquartered in Boston, Massachusetts, and operates globally through direct operations, subsidiaries, and distribution networks. The company maintains a substantial market presence in the United States, which represents its largest revenue base, while also serving customers throughout Europe, Asia-Pacific, the Middle East, and Latin America. Manufacturing, research, and commercial operations are distributed across multiple countries to support regional healthcare systems and plasma collection infrastructure.
Its international footprint is particularly significant within the plasma collection industry, where global pharmaceutical demand for plasma-derived therapies has driven continued expansion. Haemonetics supports multinational plasma collection operators and healthcare institutions across developed and emerging markets, giving the company operational exposure to both mature hospital systems and growing healthcare infrastructure investments internationally.
Leadership & Governance
Haemonetics is led by an executive team with backgrounds in medical technology, healthcare operations, and commercial strategy. Corporate governance is overseen by a board of directors and management team focused on operational execution, product innovation, and disciplined capital allocation. Public filings and investor communications have emphasized growth through innovation, portfolio optimization, and expansion into higher-acuity clinical markets.
Key executives include:
- Chris Simon – President and Chief Executive Officer
- Bill Burke – Executive Vice President, Chief Financial Officer
- Stewart Strong – President, Global Hospital Business
- Tom Szczypka – Executive Vice President and Chief Operating Officer
- Michelle Basil – Executive Vice President, Chief Human Resources Officer
- Jennifer Turi – Executive Vice President, General Counsel and Chief Compliance Officer
The company’s leadership strategy has centered on strengthening recurring revenue streams, advancing technology-enabled clinical solutions, and expanding Haemonetics’ role in plasma collection and cardiovascular care markets through targeted acquisitions and product innovation.